Arax Advisory Partners’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.14K | Buy |
68
+26
| +62% | +$819 | ﹤0.01% | 2551 |
|
|
2025
Q1 | $1.38K | Sell |
42
-80
| -66% | -$2.62K | ﹤0.01% | 2198 |
|
|
2024
Q4 | $4.41K | Hold |
122
| – | – | ﹤0.01% | 1784 |
|
|
2024
Q3 | $3.8K | Sell |
122
-17
| -12% | -$530 | ﹤0.01% | 1828 |
|
|
2024
Q2 | $3.72K | Buy |
139
+104
| +297% | +$2.78K | ﹤0.01% | 1718 |
|
|
2024
Q1 | $1.19K | Sell |
35
-37
| -51% | -$1.26K | ﹤0.01% | 1125 |
|
|
2023
Q4 | $2.08K | Buy |
72
+5
| +7% | +$145 | ﹤0.01% | 1010 |
|
|
2023
Q3 | $1.85K | Hold |
67
| – | – | ﹤0.01% | 1022 |
|
|
2023
Q2 | $2.02K | Hold |
67
| – | – | ﹤0.01% | 1000 |
|
|
2023
Q1 | $2.43K | Hold |
67
| – | – | ﹤0.01% | 978 |
|
|
2022
Q4 | $2.39K | Buy |
67
+23
| +52% | +$820 | ﹤0.01% | 920 |
|
|
2022
Q3 | $1K | Hold |
44
| – | – | ﹤0.01% | 1154 |
|
|
2022
Q2 | $1K | Hold |
44
| – | – | ﹤0.01% | 1120 |
|
|
2022
Q1 | $1K | Hold |
44
| – | – | ﹤0.01% | 1098 |
|
|
2021
Q4 | $1K | Buy |
+44
| New | +$1K | ﹤0.01% | 1084 |
|